TWI781963B - 含二硫化物細胞穿透肽及其製造與使用方法 - Google Patents

含二硫化物細胞穿透肽及其製造與使用方法 Download PDF

Info

Publication number
TWI781963B
TWI781963B TW106138809A TW106138809A TWI781963B TW I781963 B TWI781963 B TW I781963B TW 106138809 A TW106138809 A TW 106138809A TW 106138809 A TW106138809 A TW 106138809A TW I781963 B TWI781963 B TW I781963B
Authority
TW
Taiwan
Prior art keywords
arginine
peptide
pharmaceutically acceptable
acceptable salt
amino acids
Prior art date
Application number
TW106138809A
Other languages
English (en)
Chinese (zh)
Other versions
TW201823266A (zh
Inventor
德華 裴
錢自清
Original Assignee
俄亥俄州立創新基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 俄亥俄州立創新基金會 filed Critical 俄亥俄州立創新基金會
Publication of TW201823266A publication Critical patent/TW201823266A/zh
Application granted granted Critical
Publication of TWI781963B publication Critical patent/TWI781963B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW106138809A 2016-11-09 2017-11-09 含二硫化物細胞穿透肽及其製造與使用方法 TWI781963B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662419781P 2016-11-09 2016-11-09
US62/419,781 2016-11-09
US201662425550P 2016-11-22 2016-11-22
US62/425,550 2016-11-22
US201662438141P 2016-12-22 2016-12-22
US62/438,141 2016-12-22

Publications (2)

Publication Number Publication Date
TW201823266A TW201823266A (zh) 2018-07-01
TWI781963B true TWI781963B (zh) 2022-11-01

Family

ID=62109979

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106138809A TWI781963B (zh) 2016-11-09 2017-11-09 含二硫化物細胞穿透肽及其製造與使用方法

Country Status (7)

Country Link
US (2) US11351222B2 (enExample)
EP (1) EP3538125A4 (enExample)
JP (2) JP7175887B2 (enExample)
CN (2) CN110114075B (enExample)
CA (1) CA3043464A1 (enExample)
TW (1) TWI781963B (enExample)
WO (1) WO2018089648A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089648A2 (en) 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US11352394B2 (en) * 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018098226A1 (en) * 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3700548A4 (en) 2017-10-27 2021-07-21 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR THE INTRACELLULAR DELIVERY OF STONED PEPTIDES
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
US12171838B2 (en) 2018-07-02 2024-12-24 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of nucleic acids
EP3827116A4 (en) * 2018-07-23 2022-05-11 The Governors of the University of Alberta Genetically-encoded bicyclic peptide libraries
WO2020195302A1 (ja) * 2019-03-28 2020-10-01 株式会社カネカ 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用
EP4061397A4 (en) * 2019-11-21 2023-11-29 Unnatural Products Inc. CELL-PERMEABLE CYCLIC PEPTIDES AND USES THEREOF
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN115135665A (zh) * 2019-12-30 2022-09-30 俄亥俄州国家创新基金会 包含细胞穿透肽的环状蛋白
WO2022065173A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
WO2022065172A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
KR20230135586A (ko) 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도
WO2022271810A2 (en) * 2021-06-22 2022-12-29 Ohio State Innovation Foundation Bicyclic peptidyl pan-ras inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
CA2352555A1 (en) 1998-11-26 2000-06-08 Pentapharm Ag Transport system conjugate
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
EP1248642A4 (en) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
CA2425610A1 (en) 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7119070B2 (en) 2002-04-30 2006-10-10 The Regents Of The University Of California Antimicrobial theta defensins, analogs thereof, and methods of use
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2007055578A1 (en) 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
US20100221235A1 (en) 2006-02-08 2010-09-02 Diatos Compositions and Methods for Treating Lysosomal Storage Diseases
WO2008017125A1 (en) 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
WO2008067026A2 (en) * 2006-09-29 2008-06-05 Michigan Technological University Purification of synthetic oligomers
EP2155177A2 (en) 2007-04-30 2010-02-24 Intezyne Technologies Incorporated Modification of biological targeting groups for the treatment of cancer
ES2509959T5 (en) * 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
AU2011267078B2 (en) 2010-06-14 2014-09-25 F. Hoffmann-La Roche Ag Cell-penetrating peptides and uses therof
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
US20140294942A1 (en) 2011-09-07 2014-10-02 The Regents Of The University Of California Antiviral peptides effective against hepatitis c virus
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
ES2722924T3 (es) 2012-12-05 2019-08-20 Univ Heidelberg Ruprecht Karls Conjugados de proteínas y péptidos multivalentes de penetración celular y sus usos
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
WO2014190313A2 (en) 2013-05-24 2014-11-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dynorphin a analogs with bradykinin receptors specificity for modulation of neuropathic pain
WO2015021409A1 (en) 2013-08-09 2015-02-12 King's College London Compositions and methods relating to c5l2
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
JP2016534043A (ja) * 2013-10-09 2016-11-04 シナジー ファーマシューティカルズ インコーポレイテッド 炎症促進性サイトカインのダウンレギュレーションに有用なグアニル酸シクラーゼのアゴニスト
WO2015179438A1 (en) 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
CN113861268B (zh) 2014-05-21 2025-04-01 恩特拉达治疗学股份有限公司 细胞穿透肽及其制备和使用方法
WO2016054510A1 (en) 2014-10-02 2016-04-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
EP3184541A1 (en) 2015-12-23 2017-06-28 Institut Pasteur Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
WO2018089648A2 (en) * 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
TW202500573A (zh) 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Chen et al., "Dithiol amino acids can structurally shape and enhance the ligand-binding properties of polypeptides", Nature Chemistry, 2014, 6, pp 1009-1016. *
期刊 Qian et al., "Enhancing the Cell Permeability and Metabolic Stability of Peptidyl Drugs by Reversible Bicyclization", Angewandte Chemie, 2016, 55, pp 1-6.; *

Also Published As

Publication number Publication date
JP7175887B2 (ja) 2022-11-21
CA3043464A1 (en) 2018-05-17
WO2018089648A3 (en) 2018-06-21
CN117866042A (zh) 2024-04-12
WO2018089648A2 (en) 2018-05-17
CN110114075B (zh) 2024-01-12
US20190282654A1 (en) 2019-09-19
JP2023025022A (ja) 2023-02-21
US11351222B2 (en) 2022-06-07
TW201823266A (zh) 2018-07-01
JP7490735B2 (ja) 2024-05-27
JP2020502051A (ja) 2020-01-23
EP3538125A2 (en) 2019-09-18
US20220160819A1 (en) 2022-05-26
CN110114075A (zh) 2019-08-09
US11878046B2 (en) 2024-01-23
EP3538125A4 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
TWI781963B (zh) 含二硫化物細胞穿透肽及其製造與使用方法
US10501496B2 (en) Chemical synthesis and screening of bicyclic peptide libraries
CN106852146B (zh) 细胞穿透肽及其制备和使用方法
TWI853790B (zh) 細胞穿透肽序列
US11859019B2 (en) Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11987647B2 (en) Cyclic cell-penetrating peptides with one or more hydrophobic residues
US20240368224A1 (en) Bicyclic peptidyl pan-ras inhibitors
JP7780253B2 (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
US20190309020A1 (en) Cell-penetrating peptide sequences
EP4294820A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
CA3246149A1 (en) MEMBRANE TRANSLOCATION AREAS AND ASSOCIATED USES
WO2024026141A2 (en) Cyclic cell-penetrating peptides and uses thereof